期刊文献+

三苯氧胺对雌激素受体阳性乳腺癌细胞侵袭转移能力的影响及其机制 被引量:3

Effect of Tamoxifen on Invasion and Metastasis of Estrogen Receptor-Positive Breast Cancer Cell and its Mechanism
下载PDF
导出
摘要 目的探讨三苯氧胺(TAM)对雌激素受体阳性乳腺癌细胞侵袭转移能力的作用及机制。方法用不同浓度(10-7、10-8、10-9mol/L)的TAM作用于人乳腺癌MCF-7细胞株,48h后,用Transwell侵袭小室法检测细胞的侵袭能力,用RT-PCR法检测细胞基质金属蛋白酶-9(MMP-9)和金属蛋白酶组织抑制物-1(TIMP-1)基因的表达。结果上述浓度的TAM对MCF-7侵袭转移均有一定的抑制作用,均可下调其MMP-9基因表达,上调其TIMP-1基因表达,但组间比较没有显著性差异。结论 TAM可抑制雌激素受体阳性MCF-7乳腺癌细胞的侵袭和转移,在10-9mol/L~10-7mol/L之间,没有明显的剂量依赖关系;其作用机制与影响MMP-9/TIMP-1的平衡有关。 Objective To explore the effect of tamoxifen on invasion and metastasis of estrogen peceptor-positive breast cancer cell and its mechanism. Methods TAM with different concentrations(10-7,10-8,10-9 mol/L) were added to human breast cancer cell line MCF-7,after 48 h,the ability of cell invasion was detected by Transwell method,the expression of MMP-9,TIMP-1 was detected by RT-PCR method. Results TAM with above concentrations had certain inhibition on invasion and metastasis of MCF-7,and might downregulate the MMP-9 gene expression,upregulate the TIMP-1 gene expression,but there was no significant difference in these groups. Conclusion TAM can inhibit invasion and metastasis of estrogen receptor-positive MCF-7 breast cancer cell,there is no obvious dose-dependence between 10-9 mol/L and 10-7 mol/L,its mechanism is related with the balance of influencing of MMP-9/TIMP-1.
出处 《临床医学工程》 2010年第10期46-48,共3页 Clinical Medicine & Engineering
关键词 三苯氧胺 乳腺癌 逆转录聚合酶链反应 MMP-9 TIMP-1 Tamoxifen Breast cancer Reverse transcription polymerase chain reaction MMP-9 TIMP-1
  • 相关文献

参考文献16

二级参考文献64

共引文献58

同被引文献34

  • 1周政涛,王金万.LH-RH类似物在乳腺癌治疗中的应用[J].癌症进展,2005,3(2):151-155. 被引量:2
  • 2江泽飞,廖宁.早期乳腺癌术后辅助内分泌治疗的基本需求和更高追求——依西美坦辅助治疗国际临床IES-031研究结果点评[J].循证医学,2005,5(1):12-14. 被引量:6
  • 3Dixon AK,Robertson JFR,Jackson L,et al.Goserelin (Zoladex) in premenopausal advanced breast cancer: Duration of response and survival[J].Br J Cancer,2005,62(5):868. 被引量:1
  • 4Jonat W,Kaufmann M,Blamey RW, et al.A randomized study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserel in with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer[J].Eur J Cancer,1995,31 (A):137. 被引量:1
  • 5Fisher B,Costantino JP, Wickerham DL,et al.Tamoxifen for prevention ofbreast cancer: report of the National Surgical AdjuvantBreast and Bowel Project P2I Study[J].J Natl Cancer Inst,1998,90(18): 1371-1388. 被引量:1
  • 6Peto R.ATLAS(adjuvant tamoxifen,longer against shorter): Intemational randomized trial ofl0 vs 5 years of adjuvant tamoxifen among 11500 women -Preliminary results[C].SABCS, 2007,Abstract#48. 被引量:1
  • 7Locci P, Bellocchio S,Lilli C,et al.Synthesis and secretion of transforming growth factor-betal by human desmoids fibroblastcell line and its modulation by toremifene[J].J Interferon Cytokine Res,2001,21 (11):961-970. 被引量:1
  • 8Hong A,Leigh 13R.Antiproliferative properties of toremifene on ADS-related Kaposi' s sarcoma ceUs[J].Chemotherapy,2002,48 (5):238-243. 被引量:1
  • 9Mouridsen H,Gershanovich M.The role of aromatase inhibitors in the treatment of metastatic breast cancer[J].Semin Onco,1 2003,30 (1):33-45. 被引量:1
  • 10Jaeobs JR,Bovasse GB.Early and chronic stress and their relation to breast cancer[J].Psyehol Meal,2004,30(3):669-678. 被引量:1

引证文献3

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部